Rani Therapeutics Holdings Valuation
Is RANI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RANI?
Other financial metrics that can be useful for relative valuation.
|What is RANI's n/a Ratio?|
Price to Book Ratio vs Peers
How does RANI's PB Ratio compare to its peers?
|RANI PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
AVIR Atea Pharmaceuticals
TARS Tarsus Pharmaceuticals
NUVB Nuvation Bio
RANI Rani Therapeutics Holdings
Price-To-Book vs Peers: RANI is expensive based on its Price-To-Book Ratio (5.1x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does RANI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: RANI is expensive based on its Price-To-Book Ratio (5.1x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is RANI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||5.1x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate RANI's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of RANI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RANI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RANI's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.